Načítá se...
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Outcomes for those diagnosed with acute myeloid leukemia (AML) remain poor. It has been widely established that persistent residual leukemic burden, often referred to as measurable or minimal residual disease (MRD), after induction therapy or at the time of hematopoietic stem cell transplant (HSCT)...
Uloženo v:
| Vydáno v: | J Clin Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5615280/ https://ncbi.nlm.nih.gov/pubmed/28925935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm6090087 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|